Gunther E, Smith L, Kostylev M, Cox T, Kaufman A, Lee S, et al. Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Antagonists. Cell Rep. 2019;26:145-158.e8 pubmed publisher

Elgendy H, El Moghazy W, Nafady Hego H, Uemoto S. Outcome of critically-ill children after living-donor liver transplant. Exp Clin Transplant. 2015;13 Suppl 1:100-7 pubmed

Su C, Hsu C, Tsai C, Huang C, Wang S, Tang C. Resistin Promotes Angiogenesis in Endothelial Progenitor Cells Through Inhibition of MicroRNA206: Potential Implications for Rheumatoid Arthritis. Stem Cells. 2015;33:2243-55 pubmed publisher

Benajiba L, Salvado C, Dalle J, Jubert C, Galambrun C, Soulier J, et al. HLA-matched related-donor HSCT in Fanconi anemia patients conditioned with cyclophosphamide and fludarabine. Blood. 2015;125:417-8 pubmed publisher

Zhang W, Ding Y, Wu H, Chen Y, Lu H, Chen C, et al. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia. Medicine (Baltimore). 2014;93:e134 pubmed publisher

Norin S, Björkstrand B, Rommel F, Timberg L, Andersson P, Häggström J, et al. Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: results from a Swedish national observational study. Leuk Res. 2015;39:33-7 pubmed publisher

Wollmann G, Paglino J, Maloney P, Ahmadi S, van den Pol A. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector. Virology. 2015;475:1-14 pubmed publisher

Tsai C, Tsai H, Huang H, Hung C, Hsu C, Fong Y, et al. Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget. 2015;6:258-70 pubmed

Haan J, Labots M, Rausch C, Koopman M, Tol J, Mekenkamp L, et al. Genomic landscape of metastatic colorectal cancer. Nat Commun. 2014;5:5457 pubmed publisher

Khawaja M, Perkins S, Schwartz J, Robertson M, Kiel P, Sayar H, et al. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. Am J Hematol. 2015;90:97-9 pubmed publisher

Cortes J, Goldberg S, Feldman E, Rizzeri D, Hogge D, Larson M, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121:234-42 pubmed publisher

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler M, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89:E239-43 pubmed publisher

Khouri I, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014;124:2306-12 pubmed publisher

Borthakur G, Cortes J, Estey E, Jabbour E, Faderl S, O Brien S, et al. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia. Am J Hematol. 2014;89:964-8 pubmed publisher

De Astis E, Clavio M, Raiola A, Ghiso A, Guolo F, Minetto P, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol. 2014;93:2011-8 pubmed publisher

Ceppi F, Duval M, Teira P, Therrien R, Ovetchkine P, Mallette B, et al. Calcineurin inhibitor-free graft-versus-host disease prophylaxis with sirolimus and mycophenolate mofetil in a second allogeneic stem cell transplantation for engraftment failure and rituximab-refractory Epstein-Barr virus-induced posttransplant lymp. J Pediatr Hematol Oncol. 2014;36:e319-21 pubmed publisher

Gozzetti A, Candi V, Fabbri A, Schiattone L, Cencini E, Lauria F, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res. 2014;38:891-5 pubmed publisher

Kim H, Lee K, Kim I, Sohn S, Jung C, Joo Y, et al. Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG. Leuk Res. 2014;38:730-6 pubmed publisher

Kim J, Stein A, Tsai N, Schultheiss T, Palmer J, Liu A, et al. Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2014;89:75-81 pubmed publisher

Ferrero D, Crisà E, Marmont F, Audisio E, Frairia C, Giai V, et al. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ann Hematol. 2014;93:1391-400 pubmed publisher

Chantepie S, Gac A, Reman O. Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience. Leuk Res. 2014;38:569-74 pubmed publisher

Legert K, Remberger M, Ringden O, Heimdahl A, Dahllöf G. Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. Support Care Cancer. 2014;22:2133-40 pubmed publisher

Satram Hoang S, Reyes C, Hoang K, Momin F, Skettino S. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol. 2014;93:1335-44 pubmed publisher

Jayakody Arachchillage D, Hurst E, Carey P, Moses S, O Brien S, Menne T, et al. Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia. Br J Haematol. 2014;166:142-5 pubmed publisher

Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, Palacio C, et al. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 2014;28:1993-2004 pubmed publisher

Tseng J, Citrin D, Waldman M, White D, Rosenberg S, Yang J. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014;120:1426-32 pubmed publisher

Paulus A, Masood A, Miller K, Khan A, Akhtar D, Advani P, et al. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014;165:78-88 pubmed publisher

Kato K, Yoshida N, Matsumoto K, Matsuyama T. Fludarabine, cytarabine, granulocyte colony-stimulating factor and melphalan (FALG with L-PAM) as a reduced toxicity conditioning regimen in children with acute leukemia. Pediatr Blood Cancer. 2014;61:712-6 pubmed publisher

Geisler C. Cyclophosphamide for CLL: to be or not CYP2B activated?. Blood. 2013;122:4156-7 pubmed publisher

Yeh S, Lo W, Hsieh C, Bai L, Lin C, Lin P, et al. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2014;22:1199-206 pubmed publisher

De Padua L, Laurenti L, Falcucci P, D Arena G, Vannata B, Innocenti I, et al. Long-term follow up of frontline therapy with fludarabine and cyclophosphamide in chronic lymphocytic leukemia: impact of biological parameters on clinical outcome. Ann Hematol. 2014;93:1261-2 pubmed publisher

Zavdy O, Twig G, Kneller A, Yaniv G, Davidson T, Schiby G, et al. Richter syndrome: chronic lymphocytic leukemia transformation into Hodgkin's disease. Isr Med Assoc J. 2013;15:650-1 pubmed

Demir H, Bayhan T, Uner A, Kurtulan O, Karakus E, Emir S, et al. Chronic lymphocytic leukemia in a child: a challenging diagnosis in pediatric oncology practice. Pediatr Blood Cancer. 2014;61:933-5 pubmed publisher

Kater A, Spiering M, Liu R, Doreen Te Raa G, Slinger E, Tonino S, et al. Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study. Leuk Res. 2014;38:34-41 pubmed publisher

Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436-48 pubmed publisher

Hill B, Caimi P, Kindwall Keller T, Habecker B, Kalaycio M. Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL). Br J Haematol. 2014;164:297-9 pubmed publisher

Johnson G, Lin K, Cox T, Oates M, Sibson D, Eccles R, et al. CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood. 2013;122:4253-8 pubmed publisher

Abrisqueta P, Villamor N, Terol M, Gonzalez Barca E, Gonzalez M, Ferra C, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013;122:3951-9 pubmed publisher

Gao L, Gao L, Gong Y, Zhang C, Chen X, Zhang X. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Leuk Res. 2013;37:1482-7 pubmed publisher

Martin P, Byrtek M, Dawson K, Ziemiecki R, Friedberg J, Cerhan J, et al. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer. 2013;119:4129-36 pubmed publisher

Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer. 2013;119:3805-11 pubmed publisher

Prins R, Burke R, Tyner J, Druker B, Loriaux M, Spurgeon S. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013;27:2094-6 pubmed publisher

Zinzani P, Pellegrini C, Broccoli A, Casadei B, Argnani L, Pileri S. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. Am J Hematol. 2013;88:E273-6 pubmed publisher

Pantin J, Tian X, Shah A, Kurlander R, Ramos C, Cook L, et al. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes. Am J Hematol. 2013;88:874-82 pubmed publisher

Fink A, Bottcher S, Ritgen M, Fischer K, Pflug N, Eichhorst B, et al. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. 2013;27:1949-52 pubmed publisher

Lukenbill J, Kalaycio M. Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013;37:986-94 pubmed publisher

Tavil B, Erdem A, Azik F, Isik P, Metin A, Emir S, et al. Successful allogeneic hemopoietic stem cell transplantation in a case of Wiskott-Aldrich syndrome and non-Hodgkin lymphoma. Pediatr Transplant. 2013;17:E146-8 pubmed publisher

Krejci M, Doubek M, Dusek J, Brychtova Y, Racil Z, Navratil M, et al. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia. Ann Hematol. 2013;92:1397-403 pubmed publisher

Clavio M, Cruciani F, Minetto P, Guolo F, Ballerini F, Marani C, et al. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". Ann Hematol. 2013;92:1309-18 pubmed publisher

Koteda S, Nomura K, Hashiguchi M, Kawaguchi K, Oku E, Osaki K, et al. [Fatal zygomycosis caused by Mucor indicus after haplo-identical stem cell transplantation]. Rinsho Ketsueki. 2013;54:311-5 pubmed

Pan H, Ma Y, Wang D, Wang J, Jiang H, Pan S, et al. Effect of IFN-α on KC and LIX expression: role of STAT1 and its effect on neutrophil recruitment to the spleen after lipopolysaccharide stimulation. Mol Immunol. 2013;56:12-22 pubmed publisher

Kharma B, Baba T, Mandai M, Matsumura N, Murphy S, Kang H, et al. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. Int J Cancer. 2013;133:2234-44 pubmed publisher

Miano M, Poggi V, Banov L, Fioredda F, Micalizzi C, Svahn J, et al. Sirolimus as maintenance treatment in an infant with life-threatening multiresistant pure red cell anemia/autoimmune hemolytic anemia. J Pediatr Hematol Oncol. 2014;36:e145-8 pubmed publisher

Toporkiewicz M, Grzybek M, Meissner J, Michalczyk I, Dubielecka P, Korycka J, et al. Release of an ~55kDa fragment containing the actin-binding domain of β-spectrin by caspase-8 during FND-induced apoptosis depends on the presence of protein 4.1. Arch Biochem Biophys. 2013;535:205-13 pubmed publisher

Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31:1506-13 pubmed publisher

Xiang L, Li M, Liu Y, Cen J, Chen Z, Zhen X, et al. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia. Ann Hematol. 2013;92:1063-9 pubmed publisher

Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink A, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013;119:2258-67 pubmed publisher

Dörffel W, Rühl U, Lüders H, Claviez A, Albrecht M, Bökkerink J, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol. 2013;31:1562-8 pubmed publisher

Panovská A, Smolej L, Lysak D, Brychtova Y, Simkovic M, Motyčková M, et al. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. Eur J Haematol. 2013;90:479-85 pubmed publisher

Fahrmann J, Hardman W. Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine. Lipids Health Dis. 2013;12:36 pubmed publisher

Bogusz J, Majchrzak A, Mędra A, Cebula Obrzut B, Robak T, Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online). 2013;67:107-18 pubmed

Anderson E, Smith M, Martin A, Ruddock M, Lamont J, Alloush H, et al. A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines. Leuk Res. 2013;37:690-6 pubmed publisher

Schmutz J, Trechot P. [Subcutaneous panniculitis-like T-cell lymphoma following treatment with rituximab and cyclophosphamide]. Ann Dermatol Venereol. 2013;140:246-7 pubmed publisher

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, et al. In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation. Am J Hematol. 2013;88:294-300 pubmed publisher

Hussein A, Al Zaben A, Ghatasheh L, Natsheh A, Hammada T, Abdel Rahman F, et al. Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major. Pediatr Blood Cancer. 2013;60:1345-9 pubmed publisher

Radhakrishnan K, Bhatia M, Geyer M, del Toro G, Jin Z, Baker C, et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant. 2013;19:676-7 pubmed publisher

Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mul. J Hematol Oncol. 2013;6:15 pubmed publisher

Raphael M, Rottier B, Boelens J. Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation. Eur Respir J. 2013;41:479-83 pubmed publisher

Niederle N, Megdenberg D, Balleisen L, Heit W, Knauf W, Weis J, et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol. 2013;92:653-60 pubmed publisher

Kaspers G, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31:599-607 pubmed publisher

Barba P, Valcarcel D, Perez Simon J, Fernandez Aviles F, Piñana J, Martino R, et al. Impact of hyperferritinemia on the outcome of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for lymphoid malignancies. Biol Blood Marrow Transplant. 2013;19:597-601 pubmed publisher

Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, et al. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT). Eur J Haematol. 2013;90:177-86 pubmed publisher

Wong P, Fung A, Gerrie A, Moloney G, Maberley D, Rossman D, et al. IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy. Eur J Haematol. 2013;90:250-6 pubmed publisher

Novitzky N, Thomas V, du Toit C. Conditioning with purine analogs leads to good engraftment rates of immunodepleted grafts for aplastic anemia. Biol Blood Marrow Transplant. 2013;19:584-8 pubmed publisher

Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, Kurokawa M. Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. Intern Med. 2012;51:3427-30 pubmed

Diker Cohen T, Uziel O, Szyper Kravitz M, Shapira H, Natur A, Lahav M. The effect of chemotherapy on telomere dynamics: clinical results and possible mechanisms. Leuk Lymphoma. 2013;54:2023-9 pubmed publisher

Leblond V, Johnson S, Chevret S, Copplestone A, Rule S, Tournilhac O, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301-7 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Peterson L, Kim J, Kijek P, Mitchell S, Hilfinger J, Breitenbach J, et al. Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir. Bioorg Med Chem Lett. 2011;21:4045-9 pubmed publisher

Ekins S, Williams A, Xu J. A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug Metab Dispos. 2010;38:2302-8 pubmed publisher

Greene N, Fisk L, Naven R, Note R, Patel M, Pelletier D. Developing structure-activity relationships for the prediction of hepatotoxicity. Chem Res Toxicol. 2010;23:1215-22 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Diez Torrubia A, García Aparicio C, Cabrera S, De Meester I, Balzarini J, Camarasa M, et al. Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs. J Med Chem. 2010;53:559-72 pubmed publisher

Krug P, Schinazi R, Hilliard J. Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds. Antimicrob Agents Chemother. 2010;54:452-9 pubmed publisher

Shen W, Kim J, Kish P, Zhang J, Mitchell S, Gentry B, et al. Design and synthesis of vidarabine prodrugs as antiviral agents. Bioorg Med Chem Lett. 2009;19:792-6 pubmed publisher

Yu P, Hong C, Sachidanandan C, Babitt J, Deng D, Hoyng S, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4:33-41 pubmed

Terasaka T, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, et al. Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism. J Med Chem. 2005;48:4750-3 pubmed